Nav: Home

IUPUI chemists develop new technique that could speed drug development

December 01, 2016

INDIANAPOLIS -- Synthesizing useful new compounds is what pharmaceutical discovery and development is all about. Researchers at the School of Science at Indiana University-Purdue University Indianapolis have devised a method to substantially speed up the process.

The IUPUI chemists have developed and tested a new molecular binding technique that could shorten or abridge the human and animal drug discovery and development process. The new method also is potentially more economical and ecologically friendly than that currently used.

The new synthetic method is used in the production of compounds containing nitrogen. Approximately 75 percent of compounds with medicinal uses have a nitrogen atom. Such drugs are used to treat a wide range of conditions including cancers, bacterial and inflammatory diseases, attention-deficit/hyperactivity disorder, Alzheimer's disease, epilepsy, asthma, and diabetes.

Drugs are chemical compounds with differing arrangements of atoms. The new drug-synthesis method is an organic chemical process taking fewer steps than older methods. It has potential usefulness in the development of a second generation of existing drugs as well as contributing to the discovery of new pharmaceutical treatments.

"Site-selective C-H arylation of primary aliphatic amines enabled by a catalytic transient directing group" is published online ahead of print in Nature Chemistry. Authors of the paper are Haibo Ge, associate professor of chemistry and chemical biology, and post-doctoral researcher Yongbing Liu of the School of Science at IUPUI.

"Having fewer steps and simpler chemical ingredients, as our method does, has potential benefits both for the pharmaceutical industry and for patients," said Ge, the organic and medicinal chemist who developed the method and is the corresponding author of the Nature Chemistry study. "Our study showed that our technique is an advancement over the currently used method.

"While we are still at an early stage, it appears that in addition to improving the process of synthesizing molecules, our improved method makes that process more economical by saving time and labor. As it is "atom efficient," there is less waste needing disposal."

Using their new method, the IUPUI chemists successfully synthesized analogues of fingolimod, a drug used to treat relapsing forms of multiple sclerosis, an autoimmune inflammatory disease.

"Hydrocarbons -- compounds made out of carbon and hydrogen or having a carbon-hydrogen bond -- are used in daily life all the time - from clothes to toothbrushes," said Partha Basu, chair and professor of chemistry and biological chemistry at IUPUI. "These compounds are generally stable and do not react easily with common chemicals. Transformation of one hydrocarbon to another is of immense interest for developing new materials, from drugs to energy storage.

"But making such transformation in a selective way has been a challenge for more than a century. This is what Dr. Ge did using a simple but efficient process that requires fewer steps. This simplicity makes the chemistry unique, and it can have a lasting impression in the field of C-H bond activation," Basu said.
-end-
The School of Science at IUPUI and NSF grant CHE-1350541 funded the development of the new method and the Nature Chemistry study.

The School of Science at IUPUI is committed to excellence in teaching, research and service in the biological, physical, computational, behavioral and mathematical sciences. The School is dedicated to being a leading resource for interdisciplinary research and science education in support of Indiana's effort to expand and diversify its economy.

Indiana University-Purdue University Indianapolis School of Science

Related Multiple Sclerosis Articles:

AAN issues guideline on vaccines and multiple sclerosis
Can a person with multiple sclerosis (MS) get regular vaccines?
How to improve multiple sclerosis therapy
Medications currently used to treat multiple sclerosis (MS) can merely reduce relapses during the initial relapsing-remitting phase.
Vaccinations not a risk factor for multiple sclerosis
Data from over 12,000 multiple sclerosis (MS) patients formed the basis of a study by the Technical University of Munich (TUM) which investigated the population's vaccination behavior in relation to MS.
Obesity worsens disability in multiple sclerosis
Obesity is an aggravating factor in relapsing-remitting multiple sclerosis, the most common form of the disease.
A new culprit for multiple sclerosis relapses
A molecule that helps blood clot may also play a role in multiple sclerosis relapses, researchers report in the May 6, 2019 issue of PNAS.
More Multiple Sclerosis News and Multiple Sclerosis Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Erasing The Stigma
Many of us either cope with mental illness or know someone who does. But we still have a hard time talking about it. This hour, TED speakers explore ways to push past — and even erase — the stigma. Guests include musician and comedian Jordan Raskopoulos, neuroscientist and psychiatrist Thomas Insel, psychiatrist Dixon Chibanda, anxiety and depression researcher Olivia Remes, and entrepreneur Sangu Delle.
Now Playing: Science for the People

#537 Science Journalism, Hold the Hype
Everyone's seen a piece of science getting over-exaggerated in the media. Most people would be quick to blame journalists and big media for getting in wrong. In many cases, you'd be right. But there's other sources of hype in science journalism. and one of them can be found in the humble, and little-known press release. We're talking with Chris Chambers about doing science about science journalism, and where the hype creeps in. Related links: The association between exaggeration in health related science news and academic press releases: retrospective observational study Claims of causality in health news: a randomised trial This...